LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

Size: px
Start display at page:

Download "LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital"

Transcription

1 LYMPHOMA DIAGNOSIS and PROGNOSIS LC Lim Dept of Hematology Singapore General Hospital

2 OUTLINE Accurate diagnosis Define subtype : WHO classification Staging : Defines extent of involvement Prognosis Determining Prognosis Prognostic scores Communication of Diagnosis & Prognosis Six Steps

3 LYMPHOMA DIAGNOSIS

4 DIAGNOSIS OF LYMPHOMA Tissue diagnosis is essential excisional lymph node biopsy is definitive procedure Attempt to remove intact lymph node to avoid trauma to nodal architecture Fine needle aspiration (FNA) should not be used for definitive diagnosis and subtyping Lymph node Well, prepared, formalin-fixed, paraffinembedded sections required

5 Tissue Diagnosis (Lymph Node Biopsy) Consider performing lymph node biopsy if >40yrs Supraclavicular location Node diameter >2cm Firm to hard texture Lack of tenderness Do Full blood count and CXR before biopsy

6 WHO Classification of Lymphoma (2008) Internationally accepted taxonomy for lymphoma Fundamental to the classification, diagnosis and management of lymphoma 1. B-cell 2. T-cell and NK-cell 3. Hodgkin s 4. B-cell proliferations of uncertain malignant potential

7

8

9

10 Staging of Disease Stages - I, II, III, IV A or B - Based on presence/not of B symptoms fever night sweats weight loss

11 LYMPHOMA PROGNOSIS

12 Determining Prognosis Forecast of probable course and outcome of a disorder or disease Life expectancy Prognostication is both art and science, and is imperfect at best

13 How to Determine Prognosis? Sources physician predictions stage-specific survival data tumor-specific prognostic factors (eg, molecular markers, stage, grade, etc) integrated models of prognosis IPI, FLIPI, Hasenclever index for Hodgkin s lymphoma treatment- and patient-specific factors (eg, comorbid illness, performance status, and disease signs and symptoms)

14 LOW GRADE LYMPHOMA Indolent survival of untreated disease measured in years usually not curable by conventional therapy may have prolonged survival even if treatment results in only partial response EG Follicular lymphoma, CLL, Marginal zone lymphoma (eg SLVL), Hairy cell leukemia

15 AGGRESSIVE LYMPHOMA Comprises at least 10 distinct WHO categories About 50% of NHL Eg Diffuse large cell peripheral T cell anaplastic large cell lymphoma

16 AGGRESSIVE LYMPHOMA survival of untreated disease measured in months possibility of cure with conventional therapy only patients attaining complete response to therapy can expect reasonable survival or cure rapidly fatal within weeks to months if untreated or unresponsive to therapy

17 INTERNATIONAL PROGNOSTIC INDEX AGGRESSIVE NHL

18 FOLLICULAR LYMPHOMA IPI

19 Assessing Performance Status Performance status quantifies the functional status of cancer patients Tools such as the Karnofsky Scale, ECOG also captures medical care requirements Since the beginning of modern oncology in the 1940s, the ability of a patient to perform routine activities of daily living has shown the best correlation with prognosis.

20 ECOG Performance Scale 0 = fully active, able to carry out all normal activities 1 = symptoms present but able to carry out normal activities, some difficulty with more strenuous activities 2 = able to carry out normal self-care activities but limited in ability to work. Up and about more than 50% of time 3 = capable of only limited self-care. Confined to bed or chair more than 50% of waking hours 4 = completely disabled. Needs full time assistance with normal self-care activities

21 LYMPHOMA COMMUNICATING DIAGNOSIS & PROGNOSIS

22 Disclosing Diagnosis and Prognosis Research has shown that physicians are systematically overly optimistic in formulating survival estimates and even more optimistic when they disclose prognostic information to patients and/or their families Physicians' estimates of prognosis for patients in palliative care programs are overly optimistic by a factor of 3- to 5-fold -- that is 300% to 500% more optimistic than observed

23 6-Step Protocol: SPIKES SPIKES Setting 6-Step Protocol to Clarify Diagnosis and Prognosis 1. Getting started Perception Invitation Knowledge Emotion 2. What does the patient know? 3. How much does the patient want to know? 4. Share the information 5. Respond to feelings Subsequent 6. Plan next steps and follow up

24 Key Take Home Points Accurate assessment and disclosure of diagnosis and prognosis are essential for both treatment and personal decision-making for patients with cancer Consider 6-step SPIKES protocol for effective communication

25 Thank You Medicine Review Course 2011 Haematology Lymphoma Diagnosis & Prognosis

The Lymphomas. An overview..

The Lymphomas. An overview.. The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded

More information

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.

More information

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune

More information

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells

More information

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing

More information

Lymphoma and Myeloma Kris3ne Kra4s, M.D.

Lymphoma and Myeloma Kris3ne Kra4s, M.D. Lymphoma and Myeloma Kris3ne Kra4s, M.D. Hematologic Malignancies Leukemia Malignancy of hematopoie3c cells Starts in bone marrow, can spread to blood, nodes Myeloid or lymphoid Acute or chronic Lymphoma

More information

Lymphoma: The Basics. Dr. Douglas Stewart

Lymphoma: The Basics. Dr. Douglas Stewart Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What

More information

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

Indolent Lymphomas: Current. Dr. Laurie Sehn

Indolent Lymphomas: Current. Dr. Laurie Sehn Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard

More information

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey

A CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck

More information

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of

More information

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe Continuing Medical Education Announcement Harvard Medical School RSS 3081: Monthly BOTSOGO

More information

Lymphatic system component

Lymphatic system component Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most

More information

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma

More information

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are

More information

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells

More information

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 SE Scotland Cancer Network SCAN AUDIT REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008 Reports prepared by: Christine Maguire SCAN Cancer Audit Facilitator

More information

Monsanto s Spin on its Roundup herbicide is Unwinding

Monsanto s Spin on its Roundup herbicide is Unwinding Monsanto s Spin on its Roundup herbicide is Unwinding By: Thomas T. Dunbar, Esq. Recently, information about the potential danger posed by Monsanto s Roundup has surfaced as a result of information discovered

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas

More information

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish

More information

Non-Hodgkin Lymphoma in Clinically Difficult Situations

Non-Hodgkin Lymphoma in Clinically Difficult Situations Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology

More information

2012 by American Society of Hematology

2012 by American Society of Hematology 2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence

More information

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

More information

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and

More information

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma

Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Media Release Basel, 12 January 2017 Roche s subcutaneous formulation of MabThera approved in Switzerland for the treatment of common types of non-hodgkin lymphoma Administration time significantly reduced

More information

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)

Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England

More information

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification

More information

Evaluation of Neck Mass. Disclosure. Learning Objectives 3/24/2014. Karen T. Pitman MD, FACS Banner MDACC, Gilbert AZ. Nothing to disclose

Evaluation of Neck Mass. Disclosure. Learning Objectives 3/24/2014. Karen T. Pitman MD, FACS Banner MDACC, Gilbert AZ. Nothing to disclose Evaluation of Neck Mass Karen T. Pitman MD, FACS Banner MDACC, Gilbert AZ Nothing to disclose Disclosure Learning Objectives 1. Describe a systematic method to evaluate a patient with a neck mass 2. Select

More information

Lymphoma John P. Leonard, M.D.

Lymphoma John P. Leonard, M.D. Lymphoma 2017 John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department of Medicine Disclosures Consulting

More information

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology

More information

SEQUENCING FOLLICULAR LYMPHOMA

SEQUENCING FOLLICULAR LYMPHOMA SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial

More information

Bosch et al. BMC Cancer (2018) 18:276 https://doi.org/ /s y

Bosch et al. BMC Cancer (2018) 18:276 https://doi.org/ /s y Bosch et al. BMC Cancer (2018) 18:276 https://doi.org/10.1186/s12885-018-4187-y RESEARCH ARTICLE Open Access Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis

More information

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Bendamustine for relapsed follicular lymphoma refractory to rituximab LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1

More information

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long

More information

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008

MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA. April 16, 2008 MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS LYMPHOMA April 16, 2008 FACULTY COPY GOAL: Learn the appearance of normal peripheral blood elements and lymph nodes. Recognize abnormal peripheral blood

More information

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017 Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks

More information

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour 7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic

More information

Stage 4 bone cancer life expectancy

Stage 4 bone cancer life expectancy Stage 4 bone cancer life expectancy The Borg System is 100 % Stage 4 bone cancer life expectancy Stage 4 bone cancer survival rate (Prognosis). Is it possible to cure stage 4 bone cancer? What factors

More information

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University

Lymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies

More information

Leukemia And Lymphoma In The Nervous System

Leukemia And Lymphoma In The Nervous System Leukemia And Lymphoma In The Nervous System If you are searching for the book Leukemia and Lymphoma in the Nervous System in pdf format, then you've come to the right site. We presented complete variant

More information

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760

More information

Cancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka

Cancer Treatment in the Elderly. Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Cancer Treatment in the Elderly Jeffrey A. Bubis, DO, FACOI, FACP Clay County, Baptist South, and Palatka Patients 65 and older are the fastest growing segment of the US population By 2030, it will comprise

More information

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's

More information

Head and Neck: DLBCL

Head and Neck: DLBCL Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD

More information

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum

More information

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India

Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India IMPORTANCE OF COMPREHENSIVE GERIATRIC ASSESSMENT IN CANCER IN ELDERLY AN INDIAN PERSPECTIVE Dr. Joyita Banerjee PhD Scholar Dept. of Geriatric Medicine AIIMS, New Delhi, India INTRODUCTION - Cancer in

More information

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013. Lymphoma: Lympho-proliferative disorders arising from lymphocytes Heterogeneous group of disorders Differing patterns of

More information

HIV ASSOCIATED LYMPHOMA. Dr N Rapiti

HIV ASSOCIATED LYMPHOMA. Dr N Rapiti HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia

More information

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host

More information

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY Page 1 Rituximab INITIAL APPLICATION - Post-transplant The patient has B-cell post-transplant lymphoproliferative disder* To be used f a maximum of 8 treatment cycles Indications marked with * are Unapproved

More information

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma

More information

Blood Cancers in the Community

Blood Cancers in the Community Over to you, mate Blood Cancers in the Community National Rural Health Conference NZ Rural General Practice Network April 7, 2018 Brian Grainger Haematology Registrar Auckland Acknowledgements Dr James

More information

Approach to Thyroid Nodules

Approach to Thyroid Nodules Approach to Thyroid Nodules Alice Y.Y. Cheng, MD, FRCPC Twitter: @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Overview of Cutaneous Lymphomas: Diagnosis and Staging Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology Definition of Lymphoma A cancer or malignancy that comes from

More information

Lymphatic System Disorders

Lymphatic System Disorders Lymphatic System Disorders Lymphomas Malignant neoplasms involving lymphocyte proliferation in lymph nodes Specific causes not identified // Higher risk in adults who received radiation during childhood

More information

The spectrum of flow cytometry of the bone marrow

The spectrum of flow cytometry of the bone marrow The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests

More information

MANAGEMENT OF LYMPHOMAS

MANAGEMENT OF LYMPHOMAS MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association

More information

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy

More information

C r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S

C r h ist s op o h p e h r e R. R F l F ow o er e s, s M D, D M S 1 Christopher R. Flowers, MD, MS Associate Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia 2 1 Anyone can get blood cancer One

More information

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology Agenda Overview of cutaneous T and B- cell lymphomas Diagnosis, Staging, Prognosis

More information

Approach to Core Biopsy Specimens

Approach to Core Biopsy Specimens BDIAP 108th Symposium on Haematopathology Joint Meeting of the BDIAP and BLPG at-bristol, Anchor Road, Harbourside, Bristol BS1 5DB 15th - 17th May 2014 Approach to Core Biopsy Specimens Dr Stefan Dojcinov

More information

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose. Thyroid Nodule Evaluating the patient with a thyroid nodule and some management options. Miguel V. Valdez PA C Disclosure Nothing to disclose. Learning Objectives Examination of thyroid gland Options for

More information

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells

More information

Frequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma

Frequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma Original Article Frequency and Pattern of Bone Marrow Infiltration in Non- Hodgkin s Lymphoma Ayaz Lone, 1 Samina Naeem 2 Abstract Introduction: Lymphomas are divided into two, groups Hodgkin s Lymphoma

More information

Lymphoma Read with the experts

Lymphoma Read with the experts Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize

More information

Lugano classification: Role of PET-CT in lymphoma follow-up

Lugano classification: Role of PET-CT in lymphoma follow-up CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic

More information

Imbruvica. Imbruvica (ibrutinib) Description

Imbruvica. Imbruvica (ibrutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: June 22, 2017 Imbruvica Description Imbruvica

More information

Page 1 of 9 Title Authored By Course No Contact Hours 2 ABCs of Lymphoma Anita Rothera RNC, BS, CDE LYM020108 Purpose The goal of this course is to help health care professionals learn about the different

More information

During past decades, because of the lack of knowledge

During past decades, because of the lack of knowledge Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,

More information

Follicular Lymphoma 2016:

Follicular Lymphoma 2016: Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual

More information

Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?

Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype? VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence

More information

Mathias J Rummel, MD, PhD

Mathias J Rummel, MD, PhD I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track

More information

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date MP 7.03.13 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013

More information

Non-Hodgkin Lymphoma Early Detection, Diagnosis, and Staging

Non-Hodgkin Lymphoma Early Detection, Diagnosis, and Staging Non-Hodgkin Lymphoma Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that can

More information

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies Megan S. Lim MD PhD University of Pennsylvania October 8, 2018 Objectives To understand how the trend toward less invasive lymph

More information

Medcenter One Cancer Committee 2011 Annual Report

Medcenter One Cancer Committee 2011 Annual Report Medcenter One Cancer Committee 211 Annual Report With a Focus on Non-Hodgkin s Lymphoma 21 CND Cancer Registry Statistics Medcenter One Health Systems is proud to be recognized as an accredited cancer

More information

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic

More information

Notification to Implement Issued by pcodr: December 14, 2012

Notification to Implement Issued by pcodr: December 14, 2012 PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further

More information

Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich

Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich Prof. Dr. med. Beata BODE-LESNIEWSKA Institute of Pathology and Molecular Pathology University Hospital; Zurich 32 year old man 2 months history of growing left supraclavicular lymph nodes Antibiotic treatment

More information

B. Misunderstanding about clinical trials as an effective option to treatment; and

B. Misunderstanding about clinical trials as an effective option to treatment; and ANALYSIS I. INTRODUCTION In early 2012, the Lymphoma Coalition launched an on-line global survey to its 54 member organizations and their local members to help them gain a better understanding of and determine

More information

Abstracting Hematopoietic Neoplasms

Abstracting Hematopoietic Neoplasms CASE 1: LYMPHOMA PHYSICAL EXAMINATION 43yo male with a history of lower gastrointestinal bleeding and melena undergoing colonoscopy and biopsy to rule out neoplasm versus inflammation. Patient had no other

More information

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL)

Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Guidelines for the Management of Chronic Lymphocytic Leukaemia (CLL) Version History Version Date Summary of Change/Process 2.0 08.05.08 Endorsed by the Governance Committee 2.1 16.02.11 Circulated at

More information

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.

More information

Case 4 Diagnosis 2/21/2011 TGB

Case 4 Diagnosis 2/21/2011 TGB Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017

More information

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL

Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin

More information

TREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018

TREATMENT CONSIDERATIONS IN CLL/SLL AND FL. June 6, 2018 TREATMENT CONSIDERATIONS IN CLL/SLL AND FL June 6, 2018 0 PRESENTATION OVERVIEW IN CLL/SLL AND FL: Discuss key considerations that influence patient outcomes Highlight the importance of patients quality

More information

Update: Non-Hodgkin s Lymphoma

Update: Non-Hodgkin s Lymphoma 2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)

More information

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease Refer back to original requester with this paperwork and review previous

More information

Pathology of Hematopoietic and Lymphoid tissue

Pathology of Hematopoietic and Lymphoid tissue CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis

More information

Immunopathology of Lymphoma

Immunopathology of Lymphoma Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.

More information

Pathology of Hematopoietic and Lymphoid tissue

Pathology of Hematopoietic and Lymphoid tissue Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph

More information

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012

Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right

More information

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?

Lymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient? Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte

More information

Splenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc.

Splenic marginal zone NHL: Update on biology and therapy. Jonathan W. Friedberg M.D., M.M.Sc. Splenic marginal zone NHL: Update on biology and therapy Jonathan W. Friedberg M.D., M.M.Sc. Marginal zone NHL: A Neglected Lymphoma? Marginal zone NHL/MALT; 3 rd most common B-cell NHL Al-Hamadani et

More information

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009 SE Scotland Cancer Network SCAN AUDIT S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009 Dr John M Davies SCAN and NHS Lothian Dr

More information

An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review

An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review An Uncommon Presentation of Large B-cell Lymphoma of the kidney A Case Report and Literature Review CHRISTOPHER ADILETTA M.D., AJAZ SHAWL M.D. ST. JOSEPH S HEALTH, SYRACUSE, NY Our Patient Case We present

More information

Non-Hodgkin s Lymphomas Version

Non-Hodgkin s Lymphomas Version NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with

More information

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009

CHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009 LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of

More information